About Arthrosi Therapeutics
Arthrosi Therapeutics is a company based in Irvine (United States) founded in 2017 by Shunqi Yan and Litain Yeh was acquired by Swedish Orphan Biovitrum in December 2025.. Arthrosi Therapeutics has raised $200.87 million across 8 funding rounds from investors including Swedish Orphan Biovitrum. The company has 11 employees as of December 31, 2021. Arthrosi Therapeutics operates in a competitive market with competitors including Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others.
- Headquarter Irvine, United States
- Employees 11 as on 31 Dec, 2021
- Founders Shunqi Yan, Litain Yeh
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
- Legal Name Arthrosi Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$200.87 M (USD)
in 8 rounds
-
Latest Funding Round
$60.87 M (USD), Series D
Jun 06, 2025
- Investors
-
Employee Count
11
as on Dec 31, 2021
-
Acquired by
Swedish Orphan Biovitrum
(Dec 14, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Arthrosi Therapeutics
Arthrosi Therapeutics has successfully raised a total of $200.87M across 8 strategic funding rounds. The most recent funding activity was a Series D round of $60.87 million completed in June 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Series D — $60.9M
-
First Round
First Round
(29 Jun 2018)
- Investors Count Investors Count
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun, 2025 | Amount | Series D - Arthrosi Therapeutics | Valuation |
investors |
|
| Jul, 2023 | Amount | Series D - Arthrosi Therapeutics | Valuation |
investors |
|
| Mar, 2023 | Amount | Series B - Arthrosi Therapeutics | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Arthrosi Therapeutics
Arthrosi Therapeutics has secured backing from 1 investor. Prominent investors backing the company include Swedish Orphan Biovitrum. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Developer of therapies for rare diseases like Haemophilia, Inflammation, and Genetic diseases
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Arthrosi Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Arthrosi Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Arthrosi Therapeutics Comparisons
Competitors of Arthrosi Therapeutics
Arthrosi Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Jazz Pharmaceuticals, C4 Therapeutics, Erasca, MiRagen and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Small-molecule drugs for cancer treatment are developed via Degronimid platform.
|
|
| domain | founded_year | HQ Location |
Small molecule therapeutics for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Arthrosi Therapeutics
Frequently Asked Questions about Arthrosi Therapeutics
When was Arthrosi Therapeutics founded?
Arthrosi Therapeutics was founded in 2017 and raised its 1st funding round 1 year after it was founded.
Where is Arthrosi Therapeutics located?
Arthrosi Therapeutics is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Who is the current CEO of Arthrosi Therapeutics?
Litain Yeh is the current CEO of Arthrosi Therapeutics. They have also founded this company.
Is Arthrosi Therapeutics a funded company?
Arthrosi Therapeutics is a funded company, having raised a total of $200.87M across 8 funding rounds to date. The company's 1st funding round was a Series B of $15M, raised on Jun 29, 2018.
How many employees does Arthrosi Therapeutics have?
As of Dec 31, 2021, the latest employee count at Arthrosi Therapeutics is 11.
What does Arthrosi Therapeutics do?
Arthrosi Therapeutics was founded in 2017 and is located in Irvine, United States. Focus is placed on developing therapeutics targeting gout, chronic kidney diseases, and oncology. A proprietary candidate, AR882, is advanced to lower uric acid levels in gout patients via inhibition of URAT1, a kidney influx transporter protein. Operations center on biotech applications for these conditions.
Who are the top competitors of Arthrosi Therapeutics?
Arthrosi Therapeutics's top competitors include Jazz Pharmaceuticals, C4 Therapeutics and Erasca.
Who are Arthrosi Therapeutics's investors?
Arthrosi Therapeutics has 1 investor. Key investors include Swedish Orphan Biovitrum.